Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

Inclusion Criteria: * 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD Exclusion Criteria: * Age \> 14 years. * Patient weighing \< 10 kg. * History of severe Allergy * History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke. * Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past. * Evidence or history of severe, moderate, or uncontrolled systemic disease. * Inability to follow the prescribed dosing and follow-up schedule. * Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period. * Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study. * History of premature birth \<35 weeks' gestation. * Prior history of stroke in utero or other in utero insult.